Literature DB >> 27876581

Valley of death: A proposal to build a "translational bridge" for the next generation.

Nao J Gamo1, Michelle R Birknow2, Danielle Sullivan1, Mari A Kondo1, Yasue Horiuchi1, Takeshi Sakurai3, Barbara S Slusher4, Akira Sawa5.   

Abstract

There is a great need for novel drug discovery for major mental illnesses, but multiple levels of challenges exist in both academia and industry, spanning from scientific understanding and institutional infrastructure to business risk and feasibility. The "valley of death," the large gap between basic scientific research and translation to novel therapeutics, underscores the need to restructure education and academic research to cultivate the fertile interface between academia and industry. In this opinion piece, we propose strategies to educate young trainees in the process of drug discovery and development, and prepare them for careers across this spectrum. In addition, we describe a research framework that considers the disease trajectory and underlying biology of mental disorders, which will help to address the core pathophysiology in novel treatments, and may even allow early detection and intervention. We hope that these changes will increase understanding among academia, industry, and government, which will ultimately improve the diagnosis, prognosis and treatment of mental disorders.
Copyright © 2016 Elsevier Ireland Ltd and Japan Neuroscience Society. All rights reserved.

Entities:  

Keywords:  Dimensional approach; Drug development; Drug discovery; Education; Psychiatric disorders; Translational research; Valley of death

Mesh:

Substances:

Year:  2016        PMID: 27876581      PMCID: PMC5477974          DOI: 10.1016/j.neures.2016.11.003

Source DB:  PubMed          Journal:  Neurosci Res        ISSN: 0168-0102            Impact factor:   3.304


  16 in total

Review 1.  Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents.

Authors:  S Miyamoto; N Miyake; L F Jarskog; W W Fleischhacker; J A Lieberman
Journal:  Mol Psychiatry       Date:  2012-05-15       Impact factor: 15.992

2.  Trial watch: phase II and phase III attrition rates 2011-2012.

Authors:  John Arrowsmith; Philip Miller
Journal:  Nat Rev Drug Discov       Date:  2013-08       Impact factor: 84.694

Review 3.  Medicines for the mind: policy-based "pull" incentives for creating breakthrough CNS drugs.

Authors:  Dennis W Choi; Robert Armitage; Linda S Brady; Timothy Coetzee; William Fisher; Steven Hyman; Atul Pande; Steven Paul; William Potter; Benjamin Roin; Todd Sherer
Journal:  Neuron       Date:  2014-11-05       Impact factor: 17.173

4.  [Mind the gap: towards integrative perspectives of psychiatry].

Authors:  Akira Sawa
Journal:  Seishin Shinkeigaku Zasshi       Date:  2014

5.  Developing doctoral scientists for drug discovery: pluridimensional education required.

Authors:  David R Janero
Journal:  Expert Opin Drug Discov       Date:  2012-12-11       Impact factor: 6.098

6.  A room with a view of integrity and professionalism: personal reflections on teaching responsible conduct of research in the neurosciences.

Authors:  Emily Bell
Journal:  Sci Eng Ethics       Date:  2014-04-24       Impact factor: 3.525

7.  The RDoC framework: facilitating transition from ICD/DSM to dimensional approaches that integrate neuroscience and psychopathology.

Authors:  Bruce N Cuthbert
Journal:  World Psychiatry       Date:  2014-02       Impact factor: 49.548

8.  Promoting careers in academic research to psychiatry residents.

Authors:  Sotirios Posporelis; Akira Sawa; Gwenn S Smith; Maxine L Stitzer; Constantine G Lyketsos; Margaret S Chisolm
Journal:  Acad Psychiatry       Date:  2014-02-05

Review 9.  Transcending Psychosis: The Complexity of Comorbidity in Schizophrenia.

Authors:  Sun Young Yum; Michael Y Hwang; Henry A Nasrallah; Lewis A Opler
Journal:  Psychiatr Clin North Am       Date:  2016-03-30

10.  Toward the future of psychiatric diagnosis: the seven pillars of RDoC.

Authors:  Bruce N Cuthbert; Thomas R Insel
Journal:  BMC Med       Date:  2013-05-14       Impact factor: 8.775

View more
  9 in total

1.  Translational Geroscience: From invertebrate models to companion animal and human interventions.

Authors:  Mitchell B Lee; Matt Kaeberlein
Journal:  Transl Med Aging       Date:  2018-08-17

2.  Pharmacological Optimization for Successful Traumatic Brain Injury Drug Development.

Authors:  Samuel M Poloyac; Richard J Bertz; Lee A McDermott; Punit Marathe
Journal:  J Neurotrauma       Date:  2019-04-10       Impact factor: 5.269

3.  Optimized Administration of the M4 PAM VU0467154 Demonstrates Broad Efficacy, but Limited Effective Concentrations in Mecp2+/- Mice.

Authors:  Jakub Cikowski; Calista Holt; Bright Arthur; Mackenzie Smith; Sonia Gonzalez; Craig W Lindsley; Colleen M Niswender; Rocco G Gogliotti
Journal:  ACS Chem Neurosci       Date:  2022-06-07       Impact factor: 5.780

4.  Clinical and Preclinical Evidence for M1 Muscarinic Acetylcholine Receptor Potentiation as a Therapeutic Approach for Rett Syndrome.

Authors:  Mackenzie Smith; Bright Arthur; Jakub Cikowski; Calista Holt; Sonia Gonzalez; Nicole M Fisher; Sheryl Anne D Vermudez; Craig W Lindsley; Colleen M Niswender; Rocco G Gogliotti
Journal:  Neurotherapeutics       Date:  2022-06-07       Impact factor: 6.088

5.  A "Failed" Assay Development for the Discovery of Rescuing Small Molecules from the Radiation Damage.

Authors:  Kuo-Kuang Wen; Stephen Roy; Isabella M Grumbach; Meng Wu
Journal:  SLAS Discov       Date:  2021-06-19       Impact factor: 3.341

6.  The price of progress: Funding and financing Alzheimer's disease drug development.

Authors:  Jeffrey Cummings; Carl Reiber; Parvesh Kumar
Journal:  Alzheimers Dement (N Y)       Date:  2018-06-13

7.  From Genetics to Precision Therapy: Finding a Path through the Scientific Valley of Death.

Authors:  Ritika Gupta; Benjamin Gaston
Journal:  Am J Respir Cell Mol Biol       Date:  2019-12       Impact factor: 6.914

Review 8.  Drug/Lead Compound Hydroxymethylation as a Simple Approach to Enhance Pharmacodynamic and Pharmacokinetic Properties.

Authors:  Soraya S Santos; Rodrigo V Gonzaga; Cauê B Scarim; Jeanine Giarolla; Marina C Primi; Chung M Chin; Elizabeth I Ferreira
Journal:  Front Chem       Date:  2022-02-14       Impact factor: 5.221

Review 9.  Opportunities in posthemorrhagic hydrocephalus research: outcomes of the Hydrocephalus Association Posthemorrhagic Hydrocephalus Workshop.

Authors:  Jenna E Koschnitzky; Richard F Keep; David D Limbrick; James P McAllister; Jill A Morris; Jennifer Strahle; Yun C Yung
Journal:  Fluids Barriers CNS       Date:  2018-03-27
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.